The Trump administration on Wednesday issued new rules that will put some foreign investment in U.S. biotech under heightened scrutiny, a sweeping measure that comes as Asian investors pour billions into stateside drug developers.

Biotech is among 27 industries subject to Treasury Department rules, which mandate that foreign investments in “critical technologies” undergo review by the Committee on Foreign Investment in the U.S., or CFIUS. That committee has the power to block deals if it deems them a threat to national security or U.S. “technological superiority.” Those who don’t submit to the review could face fines as high as their proposed investments.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy